Results 131 to 140 of about 11,623,584 (386)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Development and biological activity of long-acting recombinant human interferon-α2b

BMC Biotechnology, 2020
Background The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
Qian Zhang, Chao Wang, Fenlian Ma, Lihong Yao, Hanchun Gao, Luyan Zhu, Lishu Zheng   +6 more
doaj   +1 more source

Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C [PDF]

, 2018
Objectives. We evaluated platelet counts in end-stage renal disease and chronic viral hepatitis. Materials and Methods. We studied 70 patients with end-stage renal disease and chronic viral hepatitis and compared them to a control group of 45 patients ...
Breaban, Iulia, Ciulei, George, Cozma, Angela, Negrean, Vasile, Orasan, Olga Hilda, Orasan, Remus Aurel, Patiu, Ioan Mihai, Sampelean, Dorel, Secara, Sorina Cezara, Sitar Taut, Adela, Stefan, Andreea Maria, Tarmure Sarlea, Simina, Urian, Laura   +12 more
core   +1 more source

Early respiratory viral infections in infants with cystic fibrosis [PDF]

, 2015
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
A Peshkin, C Castoriadis, C Hauke, C Lasch, C Mayes, C Mayes, CG Jung, CG Jung, DC Dennett, I Semetsky, I Semetsky, J Blackmore, J Campbell, J Campbell, J Cole, J Conroy, J Conroy, J Day, J Lecoq, J Parini, JC Conroy, JR Searle, JV Wertsch, K Johnstone, K Kristjansson, LA Russell-Chapin, M Currie, M Harding, M Lynch, M Merleau-Ponty, R Leitch, R Leitch, R Leitch, R Segal, RH Hopcke, S Rowland, S Walsh, T Barone, V John-Steiner, V Villate, W James, W Sorrell   +41 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Ebola viral disease and pregnancy

Obstetric Medicine, 2015
Ebola viral disease’s interaction with pregnancy is poorly understood and remains a particular challenge for medical and para-medical personnel responding to an outbreak.
B. Black, S. Caluwaerts, J. Achar
semanticscholar   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Characterization of a continuous feline mammary epithelial cell line susceptible to feline epitheliotropic viruses. [PDF]

, 2009
Mucosal epithelial cells are the primary targets for many common viral pathogens of cats. Viral infection of epithelia can damage or disrupt the epithelial barrier that protects underlying tissues.
Heymer, Anna, Liu, Hongwei, Millon, Lee, Ossiboff, Robert J, Parker, John SL, Pesavento, Patricia, Stucker, Karla M, van der List, Deborah, Wood, Jason   +8 more
core  

Nucleic acid amplification‐based methods for diagnosis of shrimp viral diseases [PDF]

, 2023
Yoonhang Lee, Jasna Vijayan, HyeongJin Roh, Jiyeon Park, Ju‐Yeop Lee, Thanh Luan Nguyen, Hyoung Jun Kim, Wi‐Sik Kim, Arun K. Dhar, Chan‐Il Park, Do‐Hyung Kim   +10 more
openalex   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source